Literature DB >> 10438715

Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis.

P Rojnuckarin1, J G Drachman, K Kaushansky.   

Abstract

Thrombopoietin (TPO) plays a critical role in megakaryocyte proliferation and differentiation. Using various cultured cell lines, several recent studies have implicated the mitogen-activated protein kinase (MAPK) pathway in megakaryocyte differentiation. In the study reported here, we examined the role played by thrombopoietin-induced MAPK activity in a cytokine-dependent cell line (BAF3/Mpl) and in primary murine megakaryocytes. In both systems, extracellular signal-regulated protein kinase (ERK) 1 and 2 MAPK phosphorylation was rapidly induced by TPO stimulation. To identify the Mpl domain responsible for MAPK activation, BAF3 cells expressing truncated forms of the Mpl receptor were studied. Phosphorylation of ERKs did not require elements of the cytoplasmic signaling domain distal to Box 2 and was not dependent on phosphorylation of the adapter protein Shc. ERK activation in murine megakaryocytes was maximal at 10 minutes and was markedly decreased over the subsequent 3 hours. Next, the physiologic consequences of MAPK inhibition were studied. Using the MAPK kinase (MEK) inhibitor, PD 98059, blockade of MAPK activity substantially reduced TPO-dependent proliferation in BAF3/Mpl cells and markedly decreased mean megakaryocyte ploidy in cultures. To exclude an indirect effect of MAPK inhibition on stromal cells in whole bone marrow, CD41(+) cells were selected and then cultured in TPO. The number of polyploid megakaryocytes derived from the CD41-selected cells was also significantly reduced by MEK inhibition, as was their geometric mean ploidy. These studies show an important role for MAPK in TPO-induced endomitosis and underscore the value of primary cells when studying the physiologic effects of signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438715

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Fine-tuning of hematopoietic stem cell homeostasis: novel role for ubiquitin ligase.

Authors:  Tomomasa Yokomizo; Elaine Dzierzak
Journal:  Genes Dev       Date:  2008-04-15       Impact factor: 11.361

Review 3.  Endoreplication: polyploidy with purpose.

Authors:  Hyun O Lee; Jean M Davidson; Robert J Duronio
Journal:  Genes Dev       Date:  2009-11-01       Impact factor: 11.361

4.  A network map of thrombopoietin signaling.

Authors:  Firdous A Bhat; Jayshree Advani; Aafaque Ahmad Khan; Sonali Mohan; Arnab Pal; Harsha Gowda; Prantar Chakrabarti; T S Keshava Prasad; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2018-07-24       Impact factor: 5.782

5.  Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Authors:  Wei Tong; Harvey F Lodish
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

6.  Thrombopoietin upregulates nucleolin mRNA and protein in thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO.

Authors:  Takatoshi Ito; Mitsuhiro Fujihara; Atsushi Oda; Shinobu Wakamoto; Miki Yamaguchi; Norio Komatsu; Hiroshi Miyazaki; Hiroshi Azuma; Hisami Ikeda; Kenji Ikebuchi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

7.  The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.

Authors:  Thomas Mercher; Glen D Raffel; Sandra A Moore; Melanie G Cornejo; Dominique Baudry-Bluteau; Nicolas Cagnard; Jonathan L Jesneck; Yana Pikman; Dana Cullen; Ifor R Williams; Koichi Akashi; Hirokazu Shigematsu; Jean-Pierre Bourquin; Marco Giovannini; William Vainchenker; Ross L Levine; Benjamin H Lee; Olivier A Bernard; D Gary Gilliland
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

8.  Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation.

Authors:  Alexandra Mazharian; Steve P Watson; Sonia Séverin
Journal:  Exp Hematol       Date:  2009-07-18       Impact factor: 3.084

9.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29

10.  Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne Delorme; Shin-Shay Tian; Christopher B Hopson; Amy J Landis; Elizabeth I Valoret; Teresa S Sellers; Jon Rosen; Stephen G Miller; Juan I Luengo; Kevin J Duffy; Julian M Jenkins
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.